SAB Biotherapeutics
SABS
42 hedge funds and large institutions have $24.5M invested in SAB Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
27,323% more capital inflows, than outflows
Capital inflows: $27.2M | Capital outflows: $99.1K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
31.27% more ownership
Funds ownership: 7.31% → 38.58% (+31%)
24% more funds holding
Funds holding: 34 → 42 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$7.7M |
| 2 |
RTW Investments
New York
|
+$7.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.84M |
| 4 |
Sessa Capital
New York
|
+$3.84M |
| 5 |
RA Capital Management
Boston,
Massachusetts
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$46K |
| 2 |
Brookstone Capital Management
Wheaton,
Illinois
|
-$17.4K |
| 3 |
LP
LGL Partners
Philadelphia,
Pennsylvania
|
-$14.5K |
| 4 |
Strategic Financial Concepts
San Antonio,
Texas
|
-$9.47K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.21K |
SABS Hedge Fund Activity: Q4 2023 in Review
42 of the 6,878 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2023, worth a combined $24.5M — up 915% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SABS positions and 5 closed out — a net gain of 9 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $7.7M. The largest seller was HighTower Advisors, exiting entirely with an estimated $46K sold.
- 42 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2023, up from 34 in Q3 2023.
- Funds reported $24.5M of SAB Biotherapeutics stock for Q4 2023, up 915% quarter-over-quarter.
- 14 funds opened new SAB Biotherapeutics positions in Q4 2023 and 5 closed out, a net change of +9 holders.
- The largest SAB Biotherapeutics buyer in Q4 2023 was BVF Inc, an estimated $7.7M added.
- The largest SAB Biotherapeutics seller in Q4 2023 was HighTower Advisors, an estimated $46K sold.
Based on aggregated 13F filings for Q4 2023.